Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a	Trial results/ publications available in trials register	Endpoints quoted in publication(s)b,c	Endpoints quoted in abstract of publication(s)b,c
Bouillanne 2013	Source:NCT00135590 Primary outcome measure(s): lean mass (dual energy X‐ray absorptiometry (dexa) and bioelectrical‐impedance analysis (bia)) ‐ time frame: 42 days	No/Yes (last verified: November 2004)	Primary outcome measure(s): lean mass (total lean soft‐tissue mass (LM) index, appendicular muscle mass (ASMM) index or body cell mass (BCM) index, which is the metabolically active compartment))	Primary outcome measure(s): body composition ((lean mass (LM), appendicular skeletal muscle mass (ASMM), and body cell mass (BCM) indices, measured by X‐ray absorptiometry combined with bioelectrical impedance analysis)
	Secondary outcome measure(s): immune functions ‐ time frame: 42 days hand‐grip strength ‐ time frame: 42 days biological nutritional parameters ‐ time frame: 42 days mortality and morbidity (infections and bedsores) ‐ time frame: 42 days ADL ‐ time frame: 42 days plasmatic amino acid levels ‐ time frame: 42 days		Secondary outcome measure(s): hand grip strength ADL score	Secondary outcome measure(s): hand grip strength ADL score
	Other outcome measure(s): ‐		Other outcome measure(s): albumin transthyretin C‐reactive protein prognostic inflammatory and nutritional index (PINI)	Other outcome measure(s): ‐
	History of changes: 6 documented changes
Faxen‐Irving 2011	Source:NCT01042340 Primary outcome measure(s): to detect a significant difference in energy intake of 48 kj/200 kcal between the groups at 5% significance level and with 80% power ‐ time frame: 5 days to 3 weeks intervention	No/Yes (last verified: December 2009)	Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
	Secondary outcome measure(s): effects on serum lipids and appetite ‐ time frame: 5 days to 3 weeks treatment		Secondary outcome measure(s): acceptance and compliance of the concept by the participants at the ward	Secondary outcome measure(s): ‐
	Other outcome measure(s): ‐		Other outcome measure(s): sample size calculation was performed: to detect a significant difference in energy intake of 200 kcal between the groups at 5% significance level and with 80% power, 27 participants in each group were needed. To allow for dropouts this was increased to 35 participants in each group nutritional assessment, by the Nutritional Risk Screening (NRS‐2002) form: evaluation of BMI, weight loss, reduced dietary intake, age 70 and presence of severe illness and a sum score (0‐7 points) was calculated biochemical indicators of nutritional status serum levels of albumin, transthyretin and insulin‐like growth factor‐1 (IGF‐1) C‐reactive protein (CRP) total cholesterol, high‐density lipoprotein (HDL) and low‐density lipoprotein (LDL) cholesterol, fasting serum triglyceride concentrations fatty acid (FA) profiles were measured in serum phospholipids function as determined by ADL according to the Katz ADL index	Other outcome measure(s): food intake and self‐rated appetite Nutritional risk screening (NRS) 2000 serum lipids and fatty acid profiles
	History of changes: 1 documented change
Holyday 2012	Source:NCT01179321 Primary outcome measure(s): length of stay	No/No (last verified: March 2006)	Primary outcome measure(s): ‐	Primary outcome measure(s): ‐
	Secondary outcome measure(s): ‐		Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
	Other outcome measure(s): ‐		Other outcome measure(s): pre‐study power analysis based on the average length of stay (LOS) of the trial population (11 d) with 0.80 power using a test with significance of 0.05, would require at least 50 participants in each group to detect a reduction in LOS of 20% the number of participants seen by a clinical dietitian, number of consults per participant and total consultation time per participant was captured from the hospital’s computerised dietitians’ statistics system timeliness of intervention was counted as days between date of admission to the ward and the date seen by the clinical dietitian weight change over the course of admission was calculated from the weight on admission and the weight at discharge deaths during admission number of presentations to emergency and number of hospital readmissions cost of hospital admission, additional costs of a screening and nutritional intervention programme	Other outcome measure(s): length of stay LOS) weight change frequency of readmission to hospital
	History of changes: 0 documented changes
Munk 2014	Source:NCT01415635 Primary outcome measure(s): Percentage of participants reaching > 75% of their calculated energy and protein requirements	No/No (last verified: December 2012)	Primary outcome measure(s): Percentage of participants reaching > 75% of their calculated energy and protein requirements	Primary outcome measure(s): Percentage of participants reaching > 75% of their calculated energy and protein requirements
	Secondary outcome measure(s): handgrip strength daily energy and protein intake use of tube feeding use of parenteral nutrition length of stay		Secondary outcome measure(s): Mean daily energy and protein intake body weight handgrip strength Length of stay number of participants receiving enteral or parenteral feeding	Secondary outcome measure(s): Mean daily energy and protein intake body weight handgrip strength Length of stay
	Other outcome measure(s): none provided		Other outcome measure(s): number of participants receiving ONS	Other outcome measure(s): ‐
	History of changes: 1 documented change
Nijs 2006	Source:NCT00114582 Primary outcome measure: nutritional status, quality of life, physical performance	No/Yes (last verified: February 2009)	Primary outcome measure(s): quality of life	Primary outcome measure(s): ‐
	Secondary outcome measure(s): ‐		Secondary outcome measure(s): ‐	Secondary outcome measure(s): ‐
	Other outcome measure(s): ‐		Other outcome measure(s): physical performance body weight energy intake	Other outcome measure(s): quality of life (perceived safety; autonomy; and sensory, physical, and psychosocial functioning) gross and fine motor function body weight
	History of changes: 4 documented changes
Salva 2011	Source:NCT00479843 Primary outcome measure(s): evaluation of the effectiveness of the intervention ‐ the main evaluation criteria which would allow the effectiveness of this intervention to be evaluated were the reduction in the loss of autonomy measured by the ADL/iADL scale ‐ time frame: baseline, 6 months, 12 months	No/Yes (last verified: January 2014)	Primary outcome measure(s): ‐	Primary outcome measure(s): main outcome measure was the reduction in the loss of autonomy ((ADL/IADL) scales) assessed at 6 and 12 months
	Secondary outcome measure(s): improvement in the participant's state of nutrition ‐ reducing the burden on carers with the Zarit scale evaluation of the use of healthcare and social resources with the RUD scale improvement of medical practice regarding nutrition (time frame: baseline, 6 months, 12 months)		Secondary outcome measure(s): improvement in nutritional state of the participant evaluated by their change in weight, BMI and MNA reduction in burden on caregiver (ZARIT scale) reduction in the use of healthcare and social resources (RUD scale)	Secondary outcome measure(s): improvement in nutritional status (Mini Nutritional Assessment (MNA), BMI, and weight changes) caregiver burden (Zarit scale)
	Other outcome measure(s): ‐		Other outcome measure(s): our primary hypothesis was that participants in the intervention group would achieve a lower level of dependency compared with participants in the usual care‐control group at 12 months. We considered a significant benefit in the intervention group to be a reduction of 30% in the proportion of participants who lost more than 0.5 points according to the ADL score (loss of autonomy) over one year	Other outcome measure(s)‐
	History of changes: 2 documented changes
Van den Berg 2015	Source:NTR2535 Primary outcome measure(s): proportion of participants who received their treatment goal. The treatment goal was to receive at least 75% of the prescribed volume of ONS during admission	No (last verified 19 Nov 2010)	Primary outcome measure(s):the percentage of participants who reached the treatment objective of at least 75% of the prescribed volume of ONS during admission	Primary outcome measure(s): The percentage of participants who consumed at least 75% of the prescribed volume of ONS
	Secondary outcome measure(s): intake (mL of ONS) (nurses and food assistants read the amount of ONS left in the bottle)		Secondary outcome measure(s): Mean intake of ONS per day in mL and energy and protein	Not stated
	Other outcome measure(s):‐		Other outcome measure(s): length of hospital stay, hospital readmissions, time to intervention, duration of intervention, mortality	Median time of taking ONS
	History of changes: No documented changes
'‐' denotes not reported aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trials registers) bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary trial) cOther outcome measures refer to all outcomes not specified as primary or secondary outcome measures ADL: activities of daily living; BMI: body mass index; EMA: European Medicines Agency; FDA: Food and Drug Administration (US); mo: month(s); N/A: not applicable; N/T: no trial document available; yr: year(s); wk: week(s); ONS oral nutritional supplement